http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
-
Neuropore Therapies (NPT) Announces Achievement of Key Program Milestone
-
Amgen (AMGN), UCB Submit Romosozumab BLA to U.S. FDA as Osteoporosis Treatment
-
Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA
-
Amgen (AMGN), UCB Phase 3 Data Comparing Romosozumab With Teriparatide Presented at ENDO
-
Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
-
Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11
-
Amgen (AMGN), UCB Announce Romosozumab Phase 3 Met Primary Endpoint in Men With Osteoporosis
-
Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
-
Amgen (AMGN), UCB Announce FRAME Phase 3 Met co-Primary Endpoints; One Secondary Endpoint Missed
-
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
-
U.S. FDA approves UCB's new epilepsy treatment, BRIVIACT®, for patients with partial-onset seizures
-
Evotec and UCB Sign Multi-Year Sample Management Agreement
-
UCB reinforces its commitment to epilepsy research with a strong presence at the 2015 American Epilepsy Society annual meeting
-
UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting
-
New UCB Data Provide Clinical Insights Into the Use of Cimzia® (certolizumab pegol) in Treating Crohn's Disease
-
New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide
-
Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide
-
UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services
-
New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.
-
UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015
-
Important UCB presence at the 2015 American Academy of Neurology Meeting
-
Dr. Reddy’s Laboratories to Acquire Select Portfolio of the Established Products Business of UCB in India

